Clinical trial
Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome
NCT00065390 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00065390 |
|---|---|
| Title | Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome |
| Official title | Pilot (Phase I-II) Study of Pyrimethamine (Daraprim) for the Treatment of the Autoimmune Lymphoproliferative Syndrome (ALPS) |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Autoimmune Disease, Lymphatic Disease, Lymphoproliferative Disorder |
| Intervention type | Drug |
| Interventions | Pyrimethamine |
| Enrollment | 8 |
| Start date | Jul 1, 2003 |
| Completion | Jun 1, 2005 |
| First posted | Jul 22, 2003 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: